资讯

Clinical Trials Arena on MSN7 小时
Corxel to begin trial of CX11 for obesity with FDA clearance
Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US Food and Drug ...
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in ...
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to ...
Investing.com India1 天
Structure Therapeutics shares rise on Pfizer’s obesity drug exit
Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has ...
Medscape13 天
Cenobamate May Cut Seizures in Drug-Resistant Epilepsy
A real-world study supports cenobamate as an effective option for patients with drug-resistant epilepsy even after multiple ...
Clinical Trials Arena11 天
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect ...
来自MSN18 天
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
The drug will come in 25 mg, 75 mg, and 150 mg tablets. Starting dosage and titration schedule is based on the patient's body weight. Soleno said diazoxide choline should be available beginning in ...
ALZFORUM17 天
Donanemab Clinical Use Growing in U.S., Rejected in Europe
Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and Drug Administration approval about nine months ago, but only a few hundred ...